The PE Ratio as of November 2024 (TTM) for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is 4.00K

According to Bristol-Myers Squibb Company PFD CONV 2’s latest financial reports and current stock price. The company's current PE Ratio is 4.00K. This represents a change of 1.85% compared to the average of 205.80 of the last 4 quarters.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Historical PE Ratio (quarterly & annually)

How has BMYMP PE Ratio performed in the past?

The mean historical PE Ratio of Bristol-Myers Squibb Company PFD CONV 2 over the last ten years is 560.68. The current 4.00K PE Ratio has changed 71.32% with respect to the historical average. Over the past ten years (40 quarters), BMYMP's PE Ratio was at its highest in in the December 2014 quarter at 30.91K. The PE Ratio was at its lowest in in the June 2020 quarter at -5088.61.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Bristol-Myers Squibb Company PFD CONV 2 PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Average PE Ratio

How has BMYMP PE Ratio performed in the past?

The current PE Ratio of Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) PE Ratio vs. Peers

How is BMYMP’s PE Ratio compared to its peers?

Bristol-Myers Squibb Company PFD CONV 2’s PE Ratio is greater than Novartis AG (12.13), less than Astellas Pharma Inc. (0), greater than Roche Holding AG (175.02), greater than Astellas Pharma Inc. (16.89), greater than Daiichi Sankyo Company, Limited (183.83), greater than AstraZeneca PLC (42.67), greater than Otsuka Holdings Co., Ltd. (34.28), greater than Chugai Pharmaceutical Co., Ltd. (40.39), greater than Roche Holding AG (16.77), greater than GSK plc (13.61), greater than Novartis AG (23.14), greater than Sanofi (12.63), greater than AstraZeneca PLC (15.42), greater than null (34.38),

Build a custom stock screener for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bristol-Myers Squibb Company PFD CONV 2 using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Bristol-Myers Squibb Company PFD CONV 2 or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.